- Home
- MRT vs CRBU Comparison
MRT vs CRBU Comparison
Compare MRT & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRT | CRBU |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.5M | 203.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MRT | CRBU |
|---|---|---|
| Price | $2.44 | $1.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.00 | ★ $9.33 |
| AVG Volume (30 Days) | 17.7K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,577,378.00 | $9,295,000.00 |
| Revenue This Year | $84.11 | N/A |
| Revenue Next Year | $125.86 | $4.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 29.67 | N/A |
| 52 Week Low | $1.97 | $0.66 |
| 52 Week High | $3.89 | $3.54 |
Technical Indicators
Market Signals| Indicator | MRT | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 55.17 | 40.56 |
| Support Level | $2.32 | $1.82 |
| Resistance Level | $2.49 | $1.91 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 77.78 | 28.90 |
Price Performance
Historical ComparisonAbout MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.